# Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2

> **NCT01200485** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 55 (actual)

## Conditions studied

- Leukemia
- Lymphoma

## Interventions

- **DRUG:** Rasburicase
- **DRUG:** Allopurinol

## Key facts

- **NCT ID:** NCT01200485
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2016-07
- **Final completion:** 2016-07
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2020-01-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01200485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01200485, "Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01200485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*